Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Corcept Therapeutics Incorporated (CORT) stocks in Canada

Learn how to easily invest in Corcept Therapeutics Incorporated stocks.

Corcept Therapeutics Incorporated is a biotechnology business based in the US. Corcept Therapeutics Incorporated stocks (CORT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $22.53 – an increase of 4.56% over the previous week. Corcept Therapeutics Incorporated employs 238 staff and has a trailing 12-month revenue of around $366 million.

How to buy stocks in Corcept Therapeutics Incorporated

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CORT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Corcept Therapeutics Incorporated stock price (NASDAQ:CORT)

Use our graph to track the performance of CORT stocks over time.

Corcept Therapeutics Incorporated shares at a glance

Information last updated 2022-05-11.
Latest market close$19.47
52-week range$15.83 - $25.68
50-day moving average $23.21
200-day moving average $21.03
Wall St. target price$26.83
PE ratio 19.4719
Dividend yield $0 (0%)
Earnings per share (TTM) $0.89

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Corcept Therapeutics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Corcept Therapeutics Incorporated price performance over time

Historical closes compared with the close of $19.47 from 2022-05-18

1 week (2022-05-12) 4.56%
1 month (2022-04-19) -16.08%
3 months (2022-02-18) -13.62%
6 months (2021-11-19) -14.87%
1 year (2021-05-19) -9.23%
2 years (2020-05-19) 31.29%
3 years (2019-05-17) 79.28%
5 years (2017-05-19) 65.28%

Is Corcept Therapeutics Incorporated under- or over-valued?

Valuing Corcept Therapeutics Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Corcept Therapeutics Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Corcept Therapeutics Incorporated's P/E ratio

Corcept Therapeutics Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Corcept Therapeutics Incorporated shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Corcept Therapeutics Incorporated's PEG ratio

Corcept Therapeutics Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Corcept Therapeutics Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Corcept Therapeutics Incorporated's EBITDA

Corcept Therapeutics Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $125.5 million.

The EBITDA is a measure of a Corcept Therapeutics Incorporated's overall financial performance and is widely used to measure a its profitability.

Corcept Therapeutics Incorporated financials

Revenue TTM $366 million
Operating margin TTM 34.01%
Gross profit TTM $360.7 million
Return on assets TTM 15.63%
Return on equity TTM 25.03%
Profit margin 30.74%
Book value $3.55
Market capitalisation $1.8 billion

TTM: trailing 12 months

Corcept Therapeutics Incorporated share dividends

We're not expecting Corcept Therapeutics Incorporated to pay a dividend over the next 12 months.

Corcept Therapeutics Incorporated share price volatility

Over the last 12 months, Corcept Therapeutics Incorporated's shares have ranged in value from as little as $15.83 up to $25.68. A popular way to gauge a stock's volatility is its "beta".

CORT.US volatility(beta: 0.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corcept Therapeutics Incorporated's is 0.5289. This would suggest that Corcept Therapeutics Incorporated's shares are less volatile than average (for this exchange).

Corcept Therapeutics Incorporated overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site